Want to see RVPH full AI Analyst Report?
Total Valuation
Reviva Pharmaceuticals Holdings has a market cap or net worth of $6.42M. The enterprise value is -$11.44.
Market Cap$6.42M
Enterprise Value-$11.44
Share Statistics
Reviva Pharmaceuticals Holdings has 13,110,377 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding13,110,377
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Reviva Pharmaceuticals Holdings’s return on equity (ROE) is -2.30 and return on invested capital (ROIC) is -223.09%.
Return on Equity (ROE)-2.30
Return on Assets (ROA)-1.25
Return on Invested Capital (ROIC)-223.09%
Return on Capital Employed (ROCE)-2.34
Revenue Per Employee0.00
Profits Per Employee-1.42M
Employee Count14
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Reviva Pharmaceuticals Holdings is ―. Reviva Pharmaceuticals Holdings’s PEG ratio is 0.01.
PE Ratio―
PS Ratio0.00
PB Ratio2.34
Price to Fair Value2.34
Price to FCF-0.82
Price to Operating Cash Flow>-0.01
PEG Ratio0.01
Income Statement
In the last 12 months, Reviva Pharmaceuticals Holdings had revenue of 0.00 and earned -19.86M in profits. Earnings per share was -5.48.
Revenue0.00
Gross Profit0.00
Operating Income-20.20M
Pretax Income-19.85M
Net Income-19.86M
EBITDA-19.83M
Earnings Per Share (EPS)-5.48
Cash Flow
In the last 12 months, operating cash flow was -5.92T and capital expenditures 0.00, giving a free cash flow of -5.92T billion.
Operating Cash Flow-5.92T
Free Cash Flow-5.92T
Free Cash Flow per Share-451.30K
Dividends & Yields
Reviva Pharmaceuticals Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.64
52-Week Price Change-94.02%
50-Day Moving Average0.49
200-Day Moving Average2.92
Relative Strength Index (RSI)49.37
Average Volume (3m)29.42K
Important Dates
Reviva Pharmaceuticals Holdings upcoming earnings date is Nov 16, 2026, TBA (Confirmed).
Last Earnings DateAug 12, 2026
Next Earnings DateNov 16, 2026
Ex-Dividend Date―
Financial Position
Reviva Pharmaceuticals Holdings as a current ratio of 2.08, with Debt / Equity ratio of 0.95%
Current Ratio2.08
Quick Ratio2.08
Debt to Market Cap0.02
Net Debt to EBITDA0.71
Interest Coverage Ratio-1.51K
Taxes
In the past 12 months, Reviva Pharmaceuticals Holdings has paid 18.89K in taxes.
Income Tax18.89K
Effective Tax Rate>-0.01
Enterprise Valuation
Reviva Pharmaceuticals Holdings EV to EBITDA ratio is -0.31, with an EV/FCF ratio of -0.25.
EV to Sales0.00
EV to EBITDA-0.31
EV to Free Cash Flow-0.25
EV to Operating Cash Flow-0.25
Balance Sheet
Reviva Pharmaceuticals Holdings has $19.89T in cash and marketable securities with $144.09B in debt, giving a net cash position of $19.75T billion.
Cash & Marketable Securities$19.89T
Total Debt$144.09B
Net Cash$19.75T
Net Cash Per Share$1.51M
Tangible Book Value Per Share$2.38
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Reviva Pharmaceuticals Holdings is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast82.20%